Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06365840
PHASE2
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
Sponsor: ImmuneOncia Therapeutics Inc.
View on ClinicalTrials.gov
Summary
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
Official title: PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMOR
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-01-13
Completion Date
2029-08
Last Updated
2025-06-18
Healthy Volunteers
No
Interventions
DRUG
IMC-001
All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
Locations (1)
Samsung Medical Center
Seoul, South Korea